학술논문
Building the Future Therapies for Down Syndrome: The Third International Conference of the T21 Research Society.
Document Type
article
Author
Dierssen, Mara; Herault, Yann; Helguera, Pablo; Martínez de Lagran, Maria; Vazquez, Anna; Christian, Bradley; Carmona-Iragui, Maria; Wiseman, Frances; Mobley, William; Fisher, Elizabeth MC; Brault, Veronique; Esbensen, Anna; Jacola, Lisa M; Potier, Marie Claude; Hamlett, Eric D; Abbeduto, Leonard; Del Hoyo Soriano, Laura; Busciglio, Jorge; Iulita, Maria Florencia; Crispino, John; Malinge, Sébastien; Barone, Eugenio; Perluigi, Marzia; Costanzo, Floriana; Delabar, Jean Maurice; Bartesaghi, Renata; Dekker, Alain D; De Deyn, Peter; Fortea Ormaechea, Juan; Shaw, Patricia A; Haydar, Tarik F; Sherman, Stephanie L; Strydom, André; Bhattacharyya, Anita
Source
Molecular syndromology. 12(4)
Subject
Language
Abstract
Research focused on Down syndrome has increased in the last several years to advance understanding of the consequences of trisomy 21 (T21) on molecular and cellular processes and, ultimately, on individuals with Down syndrome. The Trisomy 21 Research Society (T21RS) is the premier scientific organization for researchers and clinicians studying Down syndrome. The Third International Conference of T21RS, held June 6-9, 2019, in Barcelona, Spain, brought together 429 scientists, families, and industry representatives to share the latest discoveries on underlying cellular and molecular mechanisms of T21, define cognitive and behavioral challenges and better understand comorbidities associated with Down syndrome, including Alzheimer's disease and leukemia. Presentation of cutting-edge results in neuroscience, neurology, model systems, psychology, cancer, biomarkers and molecular and phar-ma-cological therapeutic approaches demonstrate the compelling interest and continuing advancement in all aspects of understanding and ameliorating conditions associated with T21.